<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2664-3243</journal-id>
<journal-title><![CDATA[Vive Revista de Salud]]></journal-title>
<abbrev-journal-title><![CDATA[Vive Rev. Salud]]></abbrev-journal-title>
<issn>2664-3243</issn>
<publisher>
<publisher-name><![CDATA[CET-BOLIVIA]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2664-32432022000300671</article-id>
<article-id pub-id-type="doi">10.33996/revistavive.v5i15.178</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Virus del papiloma humano de alto riesgo y factores asociados en mujeres de Ecuador]]></article-title>
<article-title xml:lang="en"><![CDATA[High-risk human papillomavirus and associated factors in women in Ecuador]]></article-title>
<article-title xml:lang="pt"><![CDATA[Papilomavírus humano de alto risco e fatores associados nas mulheres equatorianas]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[Zoila Katherine Salazar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cortez]]></surname>
<given-names><![CDATA[Joselyn Madelaine Heredia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Suárez]]></surname>
<given-names><![CDATA[Alicia Esperanza Zhingre]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Heredia]]></surname>
<given-names><![CDATA[Freddy Rosendo Cárdenas]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Católica de Cuenca  ]]></institution>
<addr-line><![CDATA[Cuenca ]]></addr-line>
<country>Ecuador</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<volume>5</volume>
<numero>15</numero>
<fpage>671</fpage>
<lpage>678</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_arttext&amp;pid=S2664-32432022000300671&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_abstract&amp;pid=S2664-32432022000300671&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_pdf&amp;pid=S2664-32432022000300671&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN El cáncer de cérvix en el 99% de los casos, es causado por el Virus del Papiloma Humano (VPH) de alto riesgo, su prevalencia es elevada en países de bajos ingresos debido a la escasez de recursos para realizar programas generalizados de detección precoz, inmunización y tratamiento adecuado. El objetivo de la investigación fue identificar la frecuencia y los factores de riesgo de las infecciones del VPH de alto riesgo, en mujeres de 21 a 65 años de tres cantones de la zona 6 del Ecuador, periodo 2019. Este fue un estudio analítico, de corte transversal; con una muestra de registros clínicos de 109 pacientes encuestadas a partir del proyecto de epidemiologia en la provincia de El Oro que cumplieron los criterios inclusión. Los datos se recogieron en un formulario validado por método Delphi. Se usó programa SPSS v 24, para la asociación de las variables: Intervalo de Confianza 95%, Chi cuadrado (con valor de p &lt; 0.05), Odds Ratio. Los resultados observados fueron de 31 (28,4%) casos de pacientes con VPH AR, de estas se identificó como el genotipo más común al VPH AR 39 (11,01%) en las participantes del estudio, seguido del VPH AR 31 (8,26%). Fueron factores considerados asociados a la infección del VPH AR sin significancia estadística el inicio de la vida sexual (IVSA) antes de los 20 años (OR = 1,2); y el número de parejas sexuales igual o mayor a 2 (OR = 1,7). Se concluye que el inicio de vida sexual temprano y el numero compañeros sexuales fueron factores asociados, pero sin significancia estadística.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Cervical cancer in 99% of cases is caused by high-risk Human Papillomavirus (HPV), its prevalence is high in low-income countries due to the scarcity of resources for widespread early detection programs, immunization and adequate treatment. The objective of the research was to identify the frequency and risk factors of high-risk HPV infections in women aged 21 to 65 years in three cantons of zone 6 of Ecuador, period 2019. This was an analytical, cross-sectional study; with a sample of clinical records of 109 patients surveyed from the epidemiology project in the province of El Oro who met the inclusion criteria. Data were collected in a form validated by Delphi method. SPSS v 24 software was used for the association of variables: 95% confidence interval, Chi-square (with p value &lt; 0.05), Odds Ratio. The results observed were 31 (28.4%) cases of patients with AR HPV, of which AR HPV 39 (11.01%) was identified as the most common genotype in the study participants, followed by AR HPV 31 (8.26%). Factors considered to be associated with AR HPV infection without statistical significance were sexual debut before the age of 20 years (OR = 1.2); and the number of sexual partners equal to or greater than 2 (OR = 1.7). It was concluded that early sexual debut and the number of sexual partners were associated factors, but without statistical significance.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO Em 99% dos casos, o câncer cervical é causado pelo papilomavírus humano de alto risco (HPV), e sua prevalência é alta em países de baixa renda devido à escassez de recursos para a detecção precoce generalizada, imunização e programas de tratamento adequados. O objetivo da pesquisa era identificar a freqüência e fatores de risco para infecções por HPV de alto risco em mulheres entre 21-65 anos de idade em três cantões da zona 6 do Equador, período 2019. Este foi um estudo analítico de corte transversal com uma amostra de registros clínicos de 109 pacientes pesquisados do projeto de epidemiologia na província de El Oro que preenchiam os critérios de inclusão. Os dados foram coletados em um formulário validado pelo método Delphi. O software SPSS v 24 foi utilizado para a associação de variáveis: Intervalo de confiança 95%, Qui-quadrado (com valor de p &lt; 0,05), Odds Ratio. Os resultados observados foram 31 (28,4%) casos de pacientes com AR HPV, dos quais AR HPV 39 (11,01%) foi identificado como o genótipo mais comum nos participantes do estudo, seguido por AR HPV 31 (8,26%). Fatores considerados associados à infecção por AR HPV sem significado estatístico foram a iniciação sexual (SAIV) antes dos 20 anos de idade (OR = 1,2); e número de parceiros sexuais igual ou maior que 2 (OR = 1,7). Concluímos que a estreia sexual precoce e o número de parceiros sexuais foram fatores associados, mas sem significado estatístico.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Virus del Papiloma Humano]]></kwd>
<kwd lng="es"><![CDATA[Infecciones por Papillomavirus]]></kwd>
<kwd lng="es"><![CDATA[factores de riesgo]]></kwd>
<kwd lng="es"><![CDATA[Neoplasias del Cuello Uterino]]></kwd>
<kwd lng="es"><![CDATA[Enfermedades del Cuello Uterino]]></kwd>
<kwd lng="en"><![CDATA[Alphapapillomavirus]]></kwd>
<kwd lng="en"><![CDATA[Papillomavirus Infections]]></kwd>
<kwd lng="en"><![CDATA[Risk Factors]]></kwd>
<kwd lng="en"><![CDATA[Uterine Cervical Neoplasms]]></kwd>
<kwd lng="en"><![CDATA[Uterine Cervical Diseases]]></kwd>
<kwd lng="pt"><![CDATA[Alphapapillomavirus]]></kwd>
<kwd lng="pt"><![CDATA[Infecções por Papillomavirus]]></kwd>
<kwd lng="pt"><![CDATA[Fatores de Risco]]></kwd>
<kwd lng="pt"><![CDATA[Neoplasias do Colo do Útero]]></kwd>
<kwd lng="pt"><![CDATA[Doenças do Colo do Útero]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cuzick]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Du]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Adcock]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kinney]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Joste]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[McDonald]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uptake of co-testing with HPV and cytology for cervical screening: A population-based evaluation in the United States]]></article-title>
<source><![CDATA[Gynecol Oncol]]></source>
<year>2021</year>
<volume>162</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>555-9</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vorsters]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bosch]]></surname>
<given-names><![CDATA[FX]]></given-names>
</name>
<name>
<surname><![CDATA[Poljak]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Waheed]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Stanley M]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[SM]]></surname>
<given-names><![CDATA[Garland]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HPV prevention and control - The way forward]]></article-title>
<source><![CDATA[Prev Med]]></source>
<year>2022</year>
<page-range>156</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bebyn]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[&#346;ledzi&#324;ska]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Wojtysiak]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jó&#378;wicki]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Mierzwa]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Dziedzic]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HPV RNA and DNA testing in Polish women screened for cervical cancer - A single oncological center study]]></article-title>
<source><![CDATA[Eur J Obstet Gynecol Reprod Biol]]></source>
<year>2022</year>
<page-range>129-34</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Biazin]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Concordance of AnyplexTM II HPV HR assays with reference HPV assays in cervical cancer screening: Systematic review]]></article-title>
<source><![CDATA[J Virol Methods]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kurani]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[MacLaughlin]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobson]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[St. Sauver]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Jenkins]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Socioeconomic disadvantage and human papillomavirus (HPV) vaccination uptake]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>2022</year>
<volume>40</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>471-6</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tian]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Tian]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The prognosis of HPV-associated metastatic pharyngeal patients by primary and distant site]]></article-title>
<source><![CDATA[Oral Oncol.]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Akumbom]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Reynolds]]></surname>
<given-names><![CDATA[NR]]></given-names>
</name>
<name>
<surname><![CDATA[Thayer]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Slade]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost and effectiveness of HPV vaccine delivery strategies: A systematic review]]></article-title>
<source><![CDATA[Prev Med Rep]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sendagorta-Cudós]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Burgos-Cibrián]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Iglesias]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Infecciones genitales por el virus del papiloma humano]]></article-title>
<source><![CDATA[Enfermedades Infecc Microbiol Clínica]]></source>
<year>2019</year>
<volume>37</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>324-34</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bergengren]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ryen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Flodström]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fadl]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Udumyen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Karlsson]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness and costs of an implemented primary HPV cervical screening programme in Sweden - A population based cohort study.]]></article-title>
<source><![CDATA[Prev Med Rep]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Njagi]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Ngure]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Mwaniki]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kiptoo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mugo]]></surname>
<given-names><![CDATA[NR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence and correlates of cervical squamous intraepithelial lesions among HIV-infected and uninfected women in Central Kenya]]></article-title>
<source><![CDATA[Pan Afr Med J]]></source>
<year>2021</year>
<page-range>44</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morales Martínez]]></surname>
<given-names><![CDATA[Á]]></given-names>
</name>
<name>
<surname><![CDATA[Blanco Rodríguez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Morales Martínez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Tejuca Somoano]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<source><![CDATA[Cervical cancer screening: Is active recruitment worth the effort? Aten Primaria]]></source>
<year>2015</year>
<month>/0</month>
<day>3/</day>
<volume>47</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>653-8</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lemp]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[De Neve]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Bussmann]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Manne-Goehler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Theilmann]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lifetime Prevalence of Cervical Cancer Screening in 55 Low- and Middle-Income Countries]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2020</year>
<volume>324</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1532-42</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goldfarb]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Comber]]></surname>
<given-names><![CDATA[JD.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Human papillomavirus (HPV) infection and vaccination: A cross-sectional study of college students&#8217; knowledge, awareness, and attitudes in Villanova, PA]]></article-title>
<source><![CDATA[Vaccine X]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Minchalo Muñoz]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Oleas Seminario]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
<name>
<surname><![CDATA[Bigoni Ordóñez]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalencia de los Genotipos del Virus del Papiloma Humano en mujeres de 25 a 65 años]]></article-title>
<source><![CDATA[Artículo Original. Oncol Ecuad]]></source>
<year>2020</year>
<volume>30</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>39-52</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Litwin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Donken]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Krajden]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[van Niekerk]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Naus]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High-risk HPV prevalence among women undergoing cervical cancer screening: Findings a decade after HPV vaccine implementation in British Columbia, Canada]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>2021</year>
<volume>39</volume>
<numero>36</numero>
<issue>36</issue>
<page-range>5198-204</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laberiano]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Caso]]></surname>
<given-names><![CDATA[WS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of High-risk HPV Genotypes Related to Cervical Cancer in Women of Lima-Peru Throughout the Years 2012 - 2017]]></article-title>
<source><![CDATA[J Am Soc Cytopathol]]></source>
<year>2019</year>
<volume>8</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martora]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Della Pepa]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Grimaldi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Franci]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Folliero]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Petrillo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Seven years prevalence and distribution of high and low risk HPV genotypes in women living in the metropolitan area of Naples]]></article-title>
<source><![CDATA[Cancer Epidemiol]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nejo]]></surname>
<given-names><![CDATA[YT]]></given-names>
</name>
<name>
<surname><![CDATA[Olaleye]]></surname>
<given-names><![CDATA[DO]]></given-names>
</name>
<name>
<surname><![CDATA[Odaibo]]></surname>
<given-names><![CDATA[GN.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence and Risk Factors for Genital Human Papillomavirus Infections Among Women in Southwest Nigeria]]></article-title>
<source><![CDATA[Arch Basic Appl Med]]></source>
<year>2018</year>
<month>/0</month>
<day>5/</day>
<volume>6</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>105-12</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Husaiyin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lili]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ainiwaer]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Rouzi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factors associated with high-risk HPV infection and cervical cancer screening methods among rural Uyghur women aged &gt; 30 years in Xinjiang]]></article-title>
<source><![CDATA[BMC Cancer]]></source>
<year>2018</year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mchome]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
<name>
<surname><![CDATA[Kjaer]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Manongi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Swai]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Waldstroem]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Iftner]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HPV types, cervical high-grade lesions and risk factors for oncogenic human papillomavirus infection among 3416 Tanzanian women]]></article-title>
<source><![CDATA[Sex Transm Infect]]></source>
<year>2021</year>
<volume>97</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>56-62</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iglesias-Osores]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Serquén López]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Virus papiloma humano y factores asociados en pacientes con citología desconocida atendidas en el norte de Perú]]></article-title>
<source><![CDATA[Rev Peru Ginecol Obstet.]]></source>
<year>2020</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
